GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Intrinsic Value: Projected FCF
中文

Amedisys (Amedisys) Intrinsic Value: Projected FCF

: $83.63 (As of Today)
View and export this data going back to 1994. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-24), Amedisys's Intrinsic Value: Projected FCF is $83.63. The stock price of Amedisys is $91.23. Therefore, Amedisys's Price-to-Intrinsic-Value-Projected-FCF of today is 1.1.

The historical rank and industry rank for Amedisys's Intrinsic Value: Projected FCF or its related term are showing as below:

AMED' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.77   Med: 1.81   Max: 4.14
Current: 1.09

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Amedisys was 4.14. The lowest was 0.77. And the median was 1.81.

AMED's Price-to-Projected-FCF is ranked better than
55.41% of 305 companies
in the Healthcare Providers & Services industry
Industry Median: 1.29 vs AMED: 1.09

Amedisys Intrinsic Value: Projected FCF Historical Data

The historical data trend for Amedisys's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.64 70.77 97.68 107.91 83.63

Amedisys Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.91 108.21 84.85 81.55 83.63

Competitive Comparison

For the Medical Care Facilities subindustry, Amedisys's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amedisys Price-to-Projected-FCF Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Amedisys's Price-to-Projected-FCF falls into.



Amedisys Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Amedisys's Free Cash Flow(6 year avg) = $185.27.

Amedisys's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(10.125989035996*185.26848+1066.514*0.8)/32.635
=83.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amedisys  (NAS:AMED) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Amedisys's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=91.23/83.629164920965
=1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amedisys Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Amedisys's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (Amedisys) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Executives
Allyson Guidroz officer: Chief Accounting Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth director, officer: President and CEO 200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North officer: Chief Information Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton officer: Chief People Officer C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert officer: Chief Compliance Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato officer: Chief Strategy Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter director PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins director 500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard officer: Chief Operating Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout director 2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye director AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly officer: See Remarks 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816